SCHEMBL4177283

SCHEMBL4177283

O=C(c1csc(NS(=O)(=O)c2ccccc2)n1)N1CCCCC1c1ccccn1

nearest known ligand 0.51

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
TRPC3 Q13507 2/20 0.51
TRPC6 Q9Y210 2/20 0.51
SCN9A Q15858 1/20 0.47
CPT1A P50416 7/20 0.43
CPT2 P23786 4/20 0.43
SCD5 Q86SK9 1/20 0.42
PRMT5 O14744 1/20 0.42
WDR77 Q9BQA1 1/20 0.42
ALDH1A1 P00352 2/20 0.41
USP2 O75604 1/20 0.41
LMNA P02545 1/20 0.41
MAPT P10636 1/20 0.41
SMN1; SMN2 Q16637 1/20 0.41
HSD17B10 Q99714 1/20 0.41
CPT1B Q92523 2/20 0.41
GRM4 Q14833 1/20 0.41
RAB9A P51151 2/20 0.40
NPC1 O15118 1/20 0.40
PKM P14618 1/20 0.40
KDM1A O60341 1/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4172975 1.00 TRPC3 (0.51) TRPC3TRPC6SCN9ACPT1ACPT2
SCHEMBL4169816 0.99 TRPC3 (0.51) TRPC3TRPC6SCN9ACPT1ACPT2
SCHEMBL4180201 0.97 SCN9A (0.49) TRPC3TRPC6SCN9ACPT1ACPT2
SCHEMBL4165105 0.88 TRPC3 (0.66) TRPC3TRPC6SCN9ASCD5ALDH1A1
SCHEMBL4170692 0.87 TRPC3 (0.65) TRPC3TRPC6SCN9ASCD5ALDH1A1
SCHEMBL4172925 0.85 TRPC3 (0.49) TRPC3TRPC6SCN9ACPT1ACPT2
SCHEMBL4172599 0.85 TRPC3 (0.61) TRPC3TRPC6SCN9ASCD5
SCHEMBL4180040 0.84 TRPC3 (0.44) TRPC3TRPC6SCN9ACPT1ACPT2
SCHEMBL4181512 0.84 TRPC3 (0.71) TRPC3TRPC6SCN9ASCD5PRMT5
SCHEMBL4180247 0.81 TRPC3 (0.56) TRPC3TRPC6SCN9ASCD5L3MBTL1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8357711-B2 Heterocyclic sulfonamides as inhibitors of ion channels PFIZER LIMITED (GB) 2013-01-22 US disclosed
US-20090143358-A1 INHIBITORS OF ION CHANNELS ICAGEN, INC. (US) 2009-06-04 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090143358-A1 INHIBITORS OF ION CHANNELS TRPV1, TRPV5, TRPA1 TRPC3 57/4885TRPC6 84/4885SCN9A 51/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.